Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen Daniel Wiviott, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 Jan 15; 139(3):366-375. PMID: 30586726.
    Citations:    Fields:    
  2. Bohula EA, Wiviott SD, Scirica BM. Lorcaserin Safety in Overweight or Obese Patients. N Engl J Med. 2019 01 03; 380(1):100. PMID: 30601747.
    Citations:    Fields:    Translation:Humans
  3. Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. J Am Heart Assoc. 2018 Nov 20; 7(22):e009260. PMID: 30571502.
    Citations:    Fields:    
  4. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 01 24; 380(4):347-357. PMID: 30415602.
    Citations:    Fields:    
  5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 01 05; 393(10166):31-39. PMID: 30424892.
    Citations:    Fields:    Translation:HumansPHPublic Health
  6. Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 07; 39(42):3810-3820. PMID: 30239711.
    Citations: 1     Fields:    
  7. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018 11 24; 392(10161):2269-2279. PMID: 30293771.
    Citations:    Fields:    
  8. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018 Sep 01; 3(9):823-828. PMID: 30073316.
    Citations:    Fields:    
  9. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 09 20; 379(12):1107-1117. PMID: 30145941.
    Citations:    Fields:    Translation:Humans
  10. Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation. 2018 Aug 21; 138(8):756-766. PMID: 29626068.
    Citations:    Fields:    
  11. Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, Mercuri MF, Lanz H, Antman EM, Braunwald E, Giugliano RP. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care. 2018 Jul 24; 2048872618790561. PMID: 30039978.
    Citations:    Fields:    
  12. Hinohara TT, Roe MT, White HD, Fox KAA, Bhatt DL, Hamm C, Gurbel PA, Aylward PE, Wiviott SD, Huber K, Neely ML, Ohman EM. Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). Am J Cardiol. 2018 Oct 15; 122(8):1322-1329. PMID: 30135019.
    Citations:    Fields:    
  13. Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12; 137(24):2662-2663. PMID: 29891625.
    Citations:    Fields:    
  14. Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C, Nicolau JC, Henry P, Kedev S, Wiviott SD, Sabatine MS, Mehta SR, Steg PG. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circ Cardiovasc Interv. 2018 Jun; 11(6):e006084. PMID: 29895599.
    Citations:    Fields:    
  15. Bellemain-Appaix A, Bégué C, Bhatt DL, Ducci K, Harrington RA, Roe M, Wiviott SD, Cucherat M, Silvain J, Collet JP, Bernasconi F, Montalescot G. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention. 2018 May 20; 14(1):78-85. PMID: 29469030.
    Citations:    Fields:    
  16. Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Am Heart J. 2018 Aug; 202:39-48. PMID: 29803985.
    Citations:    Fields:    
  17. Daaboul Y, Korjian S, Plotnikov AN, Burton P, Braunwald E, Wiviott SD, Gibson CM. Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2018 Mar 06; 71(9):1048-1049. PMID: 29495985.
    Citations:    Fields:    
  18. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 Mar 06; 71(9):1021-1034. PMID: 29495982.
    Citations: 1     Fields:    
  19. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018 Feb 27; 137(9):961-972. PMID: 29483172.
    Citations:    Fields:    
  20. Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD. DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018 05; 20(5):1102-1110. PMID: 29322605.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  21. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 Jun; 200:83-89. PMID: 29898853.
    Citations: 3     Fields:    
  22. Mody P, Wang T, McNamara R, Das S, Li S, Chiswell K, Tsai T, Kumbhani D, Wiviott S, Goyal A, Roe M, de Lemos JA. Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2018 01 01; 4(1):43-50. PMID: 29293980.
    Citations:    Fields:    
  23. Sabatine MS, Leiter LA, Wiviott SD. Questioning the safety and benefits of evolocumab - Authors' reply. Lancet Diabetes Endocrinol. 2018 01; 6(1):11-12. PMID: 29273161.
    Citations:    Fields:    Translation:Humans
  24. Badreldin HA, Rimsans J, Connors JM, Wiviott SD. Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report. Catheter Cardiovasc Interv. 2018 02 15; 91(3):E17-E20. PMID: 29068112.
    Citations:    Fields:    
  25. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450. PMID: 28972004.
    Citations:    Fields:    Translation:Humans
  26. Fanaroff AC, Roe MT, Clare RM, Lokhnygina Y, Navar AM, Giugliano RP, Wiviott SD, Tershakovec AM, Braunwald E, Blazing MA. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. J Am Heart Assoc. 2017 Sep 18; 6(9). PMID: 28923989.
    Citations:    Fields:    Translation:Humans
  27. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950. PMID: 28927706.
    Citations: 25     Fields:    Translation:Humans
  28. Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C, Wiviott SD, Elbez Y, Sabatine MS, Steg PG. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation. 2017 Nov 14; 136(20):1895-1907. PMID: 28893843.
    Citations:    Fields:    Translation:Humans
  29. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 09 28; 377(13):1217-1227. PMID: 28847206.
    Citations: 49     Fields:    Translation:HumansCTClinical Trials
  30. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 Jun 01; 2(6):598-607. PMID: 28291870.
    Citations: 12     Fields:    
  31. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 May 01; 2(5):547-555. PMID: 28291866.
    Citations: 10     Fields:    
  32. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S, James SK, Wallentin L, Clemmensen P, Roe MT, Ohman EM, Harrington RA, Mega JL, Bhatt DL, Sabatine MS, O'Donoghue ML. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559. PMID: 28335837.
    Citations:    Fields:    Translation:Humans
  33. Dalby AJ, Gottlieb S, Cyr DD, Magnus Ohman E, McGuire DK, Ruzyllo W, Bhatt DL, Wiviott SD, Winters KJ, Fox KAA, Armstrong PW, White HD, Prabhakaran D, Roe MT. Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. Am Heart J. 2017 Jun; 188:156-166. PMID: 28577671.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  34. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 05 04; 376(18):1713-1722. PMID: 28304224.
    Citations: 209     Fields:    Translation:Humans
  35. Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes- Marquez E, Wiviott S, Cannon CP, Braunwald E, Collins R, Landray MJ. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 05; 187:182-190. PMID: 28454801.
    Citations: 11     Fields:    Translation:Humans
  36. Bonaca MP, Wiviott SD. Prasugrel Versus Ticagrelor: Uncertainty Remains. Circulation. 2016 11 22; 134(21):1613-1616. PMID: 27881505.
    Citations:    Fields:    
  37. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27; 316(12):1289-97. PMID: 27673306.
    Citations: 34     Fields:    Translation:HumansCells
  38. Edmund Anstey D, Li S, Thomas L, Wang TY, Wiviott SD. Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. Clin Cardiol. 2016 Oct; 39(10):585-595. PMID: 27468142.
    Citations: 4     Fields:    Translation:Humans
  39. Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A, Dorobantu M, Mercuri M, Lanz H, Rutman H, Wiviott SD, Antman EM, Giugliano RP. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 07 08; 5(7). PMID: 27402235.
    Citations: 4     Fields:    Translation:Humans
  40. O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1591-9. PMID: 27043082.
    Citations: 27     Fields:    Translation:HumansPHPublic Health
  41. Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8. PMID: 27297843.
    Citations: 3     Fields:    Translation:Humans
  42. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502. PMID: 27046159.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  43. Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet JP, Delaney JT, Hulot JS, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MS. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2016 Apr; 41(3):374-83. PMID: 26573179.
    Citations: 6     Fields:    Translation:Humans
  44. Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77. PMID: 27009617.
    Citations: 4     Fields:    Translation:Humans
  45. Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med. 2016 Aug; 129(8):850-857.e2. PMID: 26994510.
    Citations: 2     Fields:    Translation:Humans
  46. Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2016 Jan 21; 37(4):412-22. PMID: 26637834; PMCID: PMC4720838.
    Citations: 1     Fields:    Translation:Humans
  47. Pursnani A, Celeng C, Schlett CL, Mayrhofer T, Zakroysky P, Lee H, Ferencik M, Fleg JL, Bamberg F, Wiviott SD, Truong QA, Udelson JE, Nagurney JT, Hoffmann U. Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain. Am J Cardiol. 2016 Feb 01; 117(3):319-24. PMID: 26762723.
    Citations: 1     Fields:    Translation:Humans
  48. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB, Braunwald E, Kereiakes DJ. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85. PMID: 26586780; PMCID: PMC4751218.
    Citations: 7     Fields:    Translation:Humans
  49. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97. PMID: 26039521.
    Citations: 331     Fields:    Translation:Humans
  50. Xu H, Li W, Yang J, Wiviott SD, Sabatine MS, Peterson ED, Xian Y, Roe MT, Zhao W, Wang Y, Tang X, Jia X, Wu Y, Gao R, Yang Y. The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. Am Heart J. 2016 May; 175:193-201.e3. PMID: 27179740.
    Citations: 6     Fields:    Translation:Humans
  51. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9. PMID: 25773607.
    Citations: 221     Fields:    Translation:Humans
  52. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26; 65(20):2211-21. PMID: 25787199; PMCID: PMC4678101.
    Citations: 30     Fields:    Translation:Humans
  53. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 07; 372(19):1791-800. PMID: 25773268.
    Citations: 103     Fields:    Translation:HumansPHPublic Health
  54. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015 Jul 18; 386(9990):292-302. PMID: 25777663.
    Citations: 9     Fields:    Translation:Humans
  55. Januzzi JL, Sharma U, Zakroysky P, Truong QA, Woodard PK, Pope JH, Hauser T, Mayrhofer T, Nagurney JT, Schoenfeld D, Peacock WF, Fleg JL, Wiviott S, Pang PS, Udelson J, Hoffmann U. Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. Am Heart J. 2015 Apr; 169(4):572-8.e1. PMID: 25819865; PMCID: PMC4380232.
    Citations: 4     Fields:    Translation:Humans
  56. Udell JA, Roe MT, Wiviott SD. Risk profile of clinical trial participants--reply. JAMA. 2015 Jan 06; 313(1):94-5. PMID: 25562279.
    Citations:    Fields:    Translation:Humans
  57. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2309-17. PMID: 25465416.
    Citations: 7     Fields:    Translation:Humans
  58. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26. PMID: 25465417.
    Citations: 3     Fields:    Translation:Humans
  59. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66. PMID: 25399658; PMCID: PMC4481318.
    Citations: 174     Fields:    Translation:Humans
  60. Puchner SB, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB, Truong QA, Wiviott SD, Fleg JL, Hoffmann U, Ferencik M. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015 Mar; 274(3):693-701. PMID: 25369449; PMCID: PMC4455680.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  61. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchástegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):468-74. PMID: 25318481.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  62. Cunningham JW, Wiviott SD. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol. 2014 Nov; 37(11):693-9. PMID: 25223901.
    Citations: 7     Fields:    Translation:Humans
  63. O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10; 312(10):1006-15. PMID: 25173516.
    Citations: 69     Fields:    Translation:HumansPHPublic Health
  64. Udell JA, Wang TY, Li S, Kohli P, Roe MT, de Lemos JA, Wiviott SD. Clinical trial participation after myocardial infarction in a national cardiovascular data registry. JAMA. 2014 Aug 27; 312(8):841-3. PMID: 25157729.
    Citations: 5     Fields:    Translation:Humans
  65. Hall HM, de Lemos JA, Enriquez JR, McGuire DK, Peng SA, Alexander KP, Roe MT, Desai N, Wiviott SD, Das SR. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014 Sep; 7(5):701-7. PMID: 25116897.
    Citations: 8     Fields:    Translation:Humans
  66. Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, Deenadayalu N, Murphy SA, Grip LT, Betcher JM, Duggal A, Dave J, Shi M, Mercuri M, Antman EM, Braunwald E. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014 Aug; 45(8):2372-8. PMID: 24947287.
    Citations: 5     Fields:    Translation:Humans
  67. Udell JA, Braunwald E, Antman EM, Antman EM, Murphy SA, Montalescot G, Wiviott SD. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv. 2014 Jun; 7(6):604-12. PMID: 24947719.
    Citations: 6     Fields:    Translation:Humans
  68. Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc. 2014 Apr 14; 3(2):e000849. PMID: 24732921; PMCID: PMC4187510.
    Citations: 13     Fields:    Translation:Humans
  69. Bonaca MP, Murphy SA, Miller D, Herrman JP, Gottlieb S, Keltai M, Menozzi A, Nicolau JC, Widimsky P, Antman EM, Wiviott SD. Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry. Clin Cardiol. 2014 May; 37(5):293-9. PMID: 24532082.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  70. Rhee JW, Wiviott SD, Scirica BM, Gibson CM, Murphy SA, Bonaca MP, Morrow DA, Mega JL. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. Clin Cardiol. 2014 Jun; 37(6):350-6. PMID: 24481910.
    Citations: 1     Fields:    Translation:Humans
  71. Waks JW, Sabatine MS, Cannon CP, Morrow DA, Gibson CM, Wiviott SD, Giugliano RP, Sloan S, Scirica BM. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6. PMID: 24452727.
    Citations: 1     Fields:    Translation:Humans
  72. Harskamp RE, Wang TY, Bhatt DL, Wiviott SD, Amsterdam EA, Li S, Thomas L, de Winter RJ, Roe MT. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. Am Heart J. 2014 Mar; 167(3):355-362.e3. PMID: 24576520.
    Citations: 2     Fields:    Translation:Humans
  73. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28; 369(22):2093-104. PMID: 24251359.
    Citations: 503     Fields:    Translation:Humans
  74. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013 Dec; 6(12):1275-81. PMID: 24239201.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  75. Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32. PMID: 24140678.
    Citations: 6     Fields:    Translation:Humans
  76. Desai NR, Peterson ED, Chen AY, Wiviott SD, Sabatine MS, Alexander KP, Roe MT, Shah BR. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. Am Heart J. 2013 Dec; 166(6):1043-1049.e1. PMID: 24268219.
    Citations: 1     Fields:    Translation:Humans
  77. Patel JH, Gupta R, Roe MT, Peng SA, Wiviott SD, Saucedo JF. Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014 Jan 15; 113(2):256-61. PMID: 24290492.
    Citations: 4     Fields:    Translation:Humans
  78. Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RP. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9. PMID: 24064010.
    Citations:    Fields:    Translation:Humans
  79. Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1145-55. PMID: 23995608.
    Citations: 5     Fields:    Translation:Humans
  80. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 03; 369(14):1317-26. PMID: 23992601.
    Citations: 516     Fields:    Translation:HumansCTClinical Trials
  81. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013 Aug 17; 382(9892):605-13. PMID: 23953385.
    Citations: 12     Fields:    Translation:Humans
  82. Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, Gibson CM. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013 Aug 15; 112(4):472-8. PMID: 23711804.
    Citations: 10     Fields:    Translation:Humans
  83. Diercks DB, Kontos MC, Hollander JE, Mumma BE, Holmes DN, Wiviott S, Saucedo JF, de Lemos JA. ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. Am J Emerg Med. 2013 Jul; 31(7):1005-11. PMID: 23702070; PMCID: PMC4045403.
    Citations: 1     Fields:    Translation:Humans
  84. Truong QA, Hayden D, Woodard PK, Kirby R, Chou ET, Nagurney JT, Wiviott SD, Fleg JL, Schoenfeld DA, Udelson JE, Hoffmann U. Sex differences in the effectiveness of early coronary computed tomographic angiography compared with standard emergency department evaluation for acute chest pain: the rule-out myocardial infarction with Computer-Assisted Tomography (ROMICAT)-II Trial. Circulation. 2013 Jun 25; 127(25):2494-502. PMID: 23685743; PMCID: PMC3753028.
    Citations: 12     Fields:    Translation:Humans
  85. Scirica BM, Kadakia MB, de Lemos JA, Roe MT, Morrow DA, Li S, Wiviott SD, Kontos MC. Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. Clin Chem. 2013 Aug; 59(8):1205-14. PMID: 23630179.
    Citations: 6     Fields:    Translation:Humans
  86. Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RP. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7. PMID: 23520015.
    Citations: 2     Fields:    Translation:Humans
  87. Steg PG, Mehta SR, Pollack CV, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J. 2012 Dec; 164(6):817-24.e13. PMID: 23194481.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  88. Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald E. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6. PMID: 23131034.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  89. Shah RV, Holmes D, Anderson M, Wang TY, Kontos MC, Wiviott SD, Scirica BM. Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. Circ Heart Fail. 2012 Nov; 5(6):693-702. PMID: 23051950.
    Citations: 9     Fields:    Translation:Humans
  90. Vavalle JP, Lopes RD, Chen AY, Newby LK, Wang TY, Shah BR, Ho PM, Wiviott SD, Peterson ED, Roe MT, Granger CB. Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. Am J Med. 2012 Nov; 125(11):1085-94. PMID: 22921886; PMCID: PMC3884687.
    Citations: 5     Fields:    Translation:Humans
  91. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, Pope JH, Hauser TH, White CS, Weiner SG, Kalanjian S, Mullins ME, Mikati I, Peacock WF, Zakroysky P, Hayden D, Goehler A, Lee H, Gazelle GS, Wiviott SD, Fleg JL, Udelson JE. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012 Jul 26; 367(4):299-308. PMID: 22830462; PMCID: PMC3662217.
    Citations: 116     Fields:    Translation:Humans
  92. O'Donoghue ML, Bhatt DL, Flather MD, Goto S, Angiolillo DJ, Goodman SG, Zeymer U, Aylward PE, Montalescot G, Ziecina R, Kobayashi H, Ren F, Wiviott SD. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis. 2012 Jul; 34(1):36-43. PMID: 22653705.
    Citations: 2     Fields:    Translation:Humans
  93. Maddox TM, Ho PM, Tsai TT, Wang TY, Li S, Peng SA, Wiviott SD, Masoudi FA, Rumsfeld JS. Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Jul 01; 5(4):523-31. PMID: 22570355.
    Citations: 3     Fields:    Translation:Humans
  94. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13. PMID: 22443427.
    Citations: 152     Fields:    Translation:HumansPHPublic Health
  95. Chin CT, Wang TY, Li S, Wiviott SD, deLemos JA, Kontos MC, Peterson ED, Roe MT. Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. Clin Cardiol. 2012; 35(7):424-9. PMID: 22434769.
    Citations: 8     Fields:    Translation:Humans
  96. Hoffmann U, Truong QA, Fleg JL, Goehler A, Gazelle S, Wiviott S, Lee H, Udelson JE, Schoenfeld D. Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. Am Heart J. 2012 Mar; 163(3):330-8, 338.e1. PMID: 22424002; PMCID: PMC3736358.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  97. Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation. 2012 Mar 20; 125(11):1414-23. PMID: 22319105.
    Citations: 3     Fields:    Translation:Humans
  98. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31; 125(4):577-83. PMID: 22199016.
    Citations: 19     Fields:    Translation:HumansCells
  99. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012 Jan 24; 125(3):497-504. PMID: 22179533.
    Citations: 16     Fields:    Translation:Humans
  100. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 05; 366(1):9-19. PMID: 22077192.
    Citations: 252     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  101. Wiviott SD, Hochholzer W. On-clopidogrel platelet reactivity: a target in sight? J Am Coll Cardiol. 2011 Nov 01; 58(19):1955-7. PMID: 22032705.
    Citations:    Fields:    Translation:Humans
  102. Melloni C, Roe MT, Chen AY, Wang TY, Wiviott SD, Ho PM, Peterson ED, Alexander KP. Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):603-9. PMID: 21988922.
    Citations:    Fields:    Translation:Humans
  103. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2011 Sep; 4(9):1002-8. PMID: 21939940.
    Citations: 15     Fields:    Translation:Humans
  104. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011 Sep; 162(3):518-26.e5. PMID: 21884870.
    Citations: 11     Fields:    Translation:HumansCells
  105. Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011 Oct 01; 108(7):905-11. PMID: 21816379.
    Citations: 6     Fields:    Translation:Humans
  106. Wiviott SD. ILLUMINATE sheds more light. Circulation. 2011 Aug 02; 124(5):536-7. PMID: 21768540.
    Citations: 1     Fields:    Translation:Humans
  107. Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. PMID: 21713327.
    Citations: 2     Fields:    Translation:Humans
  108. Mathews R, Peterson ED, Li S, Roe MT, Glickman SW, Wiviott SD, Saucedo JF, Antman EM, Jacobs AK, Wang TY. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. Circulation. 2011 Jul 12; 124(2):154-63. PMID: 21690494.
    Citations: 24     Fields:    Translation:Humans
  109. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14; 123(23):2736-47. PMID: 21670242.
    Citations: 256     Fields:    Translation:Humans
  110. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011 Jun 14; 123(23):2681-9. PMID: 21606391.
    Citations: 14     Fields:    Translation:Humans
  111. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1. PMID: 21641362.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  112. Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation. 2011 May 03; 123(17):1854-63. PMID: 21502571.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  113. O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation. 2011 May 03; 123(17):1843-53. PMID: 21502577.
    Citations: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  114. Don CW, Roe MT, Li S, Fraulo E, Pomerantsev E, Palacios I, Wiviott SD. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. Am Heart J. 2011 Apr; 161(4):689-97. PMID: 21473967; PMCID: PMC3086530.
    Citations: 2     Fields:    Translation:Humans
  115. Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, Roe MT, Schubart UK, Fox CS. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011 Apr; 161(4):657-663.e1. PMID: 21473963.
    Citations: 8     Fields:    Translation:Humans
  116. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6. PMID: 21420059; PMCID: PMC3743416.
    Citations: 3     Fields:    Translation:Humans
  117. Desai NR, Beckman J, Wiviott SD. When stable becomes unstable: the perils of impersonal medicine. Circulation. 2011 Jan 25; 123(3):335-41. PMID: 21263006.
    Citations:    Fields:    Translation:Humans
  118. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010 Dec; 160(6):1035-41, 1041.e1. PMID: 21146655.
    Citations: 36     Fields:    Translation:Humans
  119. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, Merkely B, Baracioli L, Schersten F, Seabro-Gomes R, Braunwald E, Wiviott SD. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012 Mar 22; 155(3):424-9. PMID: 21093072.
    Citations: 1     Fields:    Translation:Humans
  120. Forman DE, Chen AY, Wiviott SD, Wang TY, Magid DJ, Alexander KP. Comparison of outcomes in patients aged <75, 75 to 84, and = 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). Am J Cardiol. 2010 Nov 15; 106(10):1382-8. PMID: 21059425.
    Citations: 6     Fields:    Translation:Humans
  121. Wiviott SD, Mega JL. Another step on the road to tailored antiplatelet therapy. J Am Coll Cardiol. 2010 Nov 09; 56(20):1637-8. PMID: 21050972.
    Citations: 1     Fields:    Translation:Humans
  122. Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77. PMID: 21087753.
    Citations: 18     Fields:    Translation:Humans
  123. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30. PMID: 20978260; PMCID: PMC3048820.
    Citations: 195     Fields:    Translation:Humans
  124. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16; 376(9749):1312-9. PMID: 20801494; PMCID: PMC3036672.
    Citations: 100     Fields:    Translation:Humans
  125. Pride YB, Tung P, Mohanavelu S, Zorkun C, Wiviott SD, Antman EM, Giugliano R, Braunwald E, Gibson CM. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. JACC Cardiovasc Interv. 2010 Aug; 3(8):806-11. PMID: 20723851.
    Citations: 7     Fields:    Translation:HumansCells
  126. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010 Jul 27; 122(4):394-403. PMID: 20660815.
    Citations: 13     Fields:    Translation:Humans
  127. Wiviott SD, Antman EM, Braunwald E. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol. 2010 Jul 15; 106(2):293-4. PMID: 20599020.
    Citations:    Fields:    Translation:Humans
  128. Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, Wiviott S, Peterson ED. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010 Jul; 160(1):80-87.e3. PMID: 20598976.
    Citations: 17     Fields:    Translation:Humans
  129. Lopes RD, Peterson ED, Chen AY, Roe MT, Wang TY, Ohman EM, Magid DJ, Ho PM, Wiviott SD, Scirica BM, Alexander KP. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010 Jun; 3(6):669-77. PMID: 20630461.
    Citations: 7     Fields:    Translation:Humans
  130. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26; 121(3):357-65. PMID: 20065168.
    Citations: 68     Fields:    Translation:Humans
  131. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62. PMID: 20102867.
    Citations:    Fields:    Translation:Humans
  132. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010 Jan 05; 121(1):71-9. PMID: 20026770.
    Citations: 25     Fields:    Translation:Humans
  133. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62. PMID: 20082923.
    Citations: 25     Fields:    Translation:HumansPHPublic Health
  134. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J. 2009 Sep; 158(3):e21-6. PMID: 19699846.
    Citations: 6     Fields:    Translation:Humans
  135. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-997. PMID: 19726078.
    Citations: 120     Fields:    Translation:Humans
  136. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18; 54(8):678-85. PMID: 19679245.
    Citations: 14     Fields:    Translation:Humans
  137. Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Drugs. 2009 Jul 30; 69(11):1433-43. PMID: 19634922.
    Citations: 3     Fields:    Translation:Humans
  138. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009 Aug; 49(8):984-98. PMID: 19546250.
    Citations: 14     Fields:    Translation:Humans
  139. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 02; 119(21):2758-64. PMID: 19451347.
    Citations: 23     Fields:    Translation:Humans
  140. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. PMID: 19435740.
    Citations: 36     Fields:    Translation:HumansCells
  141. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19; 119(19):2553-60. PMID: 19414633.
    Citations: 117     Fields:    Translation:HumansCells
  142. Wiviott SD, Mohanavelu S, Raichlen JS, Cain VA, Nissen SE, Libby P. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol. 2009 Jul 01; 104(1):29-35. PMID: 19576317.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  143. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28; 373(9665):723-31. PMID: 19249633.
    Citations: 155     Fields:    Translation:Humans
  144. Truong QA, Cannon CP, Zakai NA, Rogers IS, Giugliano RP, Wiviott SD, McCabe CH, Morrow DA, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1. PMID: 19332194; PMCID: PMC2694948.
    Citations: 4     Fields:    Translation:Humans
  145. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Am J Cardiol. 2009 Apr 15; 103(8):1056-60. PMID: 19361589.
    Citations: 2     Fields:    Translation:Humans
  146. Diercks DB, Kontos MC, Chen AY, Pollack CV, Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, Roe MT. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009 Jan 13; 53(2):161-6. PMID: 19130984.
    Citations: 27     Fields:    Translation:Humans
  147. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22; 360(4):354-62. PMID: 19106084.
    Citations: 434     Fields:    Translation:Humans
  148. Wiviott SD. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiol Clin. 2008 Nov; 26(4):629-37. PMID: 18929236.
    Citations: 1     Fields:    Translation:Humans
  149. Stephen D Wiviott (Editor). Antiplatelet Therapy in Ischemic Heart Disease, Stephen D. Wiviott (Editor). 2008.
  150. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008 Oct 14; 118(16):1626-36. PMID: 18757948.
    Citations: 106     Fields:    Translation:Humans
  151. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008 Oct; 29(20):2473-9. PMID: 18682445; PMCID: PMC2567025.
    Citations: 21     Fields:    Translation:HumansPHPublic Health
  152. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 01; 102(5):552-8. PMID: 18721511.
    Citations: 2     Fields:    Translation:Humans
  153. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008 May 27; 51(21):2028-33. PMID: 18498956.
    Citations: 29     Fields:    Translation:Humans
  154. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 Apr 19; 371(9621):1353-63. PMID: 18377975.
    Citations: 56     Fields:    Translation:Humans
  155. Wiviott SD, Braunwald E, Murphy SA, Antman EM. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Am J Cardiol. 2008 May 01; 101(9):1367-70. PMID: 18435974.
    Citations:    Fields:    Translation:Humans
  156. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20. PMID: 18481817.
    Citations: 4     Fields:    Translation:Humans
  157. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36. PMID: 18481821.
    Citations: 2     Fields:    Translation:HumansCells
  158. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9. PMID: 18481818.
    Citations: 3     Fields:    Translation:HumansCells
  159. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6. PMID: 18481816.
    Citations: 7     Fields:    Translation:HumansCells
  160. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1. PMID: 18481815.
    Citations:    Fields:    Translation:HumansCells
  161. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35. PMID: 18481820.
    Citations: 1     Fields:    Translation:HumansCells
  162. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7. PMID: 18481819.
    Citations:    Fields:    Translation:HumansCells
  163. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. PMID: 18056526.
    Citations: 123     Fields:    Translation:HumansCTClinical Trials
  164. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007 Nov 27; 50(22):2117-24. PMID: 18036447.
    Citations: 41     Fields:    Translation:Humans
  165. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15; 357(20):2001-15. PMID: 17982182.
    Citations: 788     Fields:    Translation:HumansCTClinical Trials
  166. Ruff CT, Wiviott SD, Morrow DA, Mohanavelu S, Murphy SA, Antman EM, Braunwald E. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. Am J Med. 2007 Nov; 120(11):993-8. PMID: 17976428.
    Citations: 3     Fields:    Translation:Humans
  167. Wiviott SD and Giugliano RP. Unstable Angina and Non-ST Elevation Myocardial Infarction. Cardiovascular Therapeutics. A Companion to Braunwald's Heart Disease. EM Antman, Editor. 2007; 221-245.
  168. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, Gibson CM, Antman EM. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8. PMID: 18082517.
    Citations: 2     Fields:    Translation:Humans
  169. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84. PMID: 17917707.
    Citations: 6     Fields:    Translation:HumansCells
  170. Wiviott SD, de Lemos JA. Antiplatelet agents make a comeback in ST-elevation myocardial infarction. Am Heart J. 2007 Oct; 154(4):603-6. PMID: 17892976.
    Citations:    Fields:    Translation:Humans
  171. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7. PMID: 17717132.
    Citations: 12     Fields:    Translation:Humans
  172. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 01; 100(7):1047-51. PMID: 17884359.
    Citations: 19     Fields:    Translation:Humans
  173. Rich JD, Wiviott SD. New antiplatelet therapies for acute coronary syndromes. Curr Cardiol Rep. 2007 Jul; 9(4):303-11. PMID: 17601397.
    Citations:    Fields:    Translation:HumansCells
  174. Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald E. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6. PMID: 17600039.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  175. Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007 Jun 26; 49(25):2398-407. PMID: 17599602.
    Citations: 9     Fields:    Translation:Humans
  176. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 Jan; 153(1):66.e9-16. PMID: 17174640.
    Citations: 85     Fields:    Translation:HumansCellsCTClinical Trials
  177. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec; 17(6):626-30. PMID: 17095906.
    Citations: 5     Fields:    Translation:Humans
  178. Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 01; 99(3):344-8. PMID: 17261395.
    Citations: 1     Fields:    Translation:Humans
  179. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation. 2006 Nov 28; 114(22):e600-6. PMID: 17130347.
    Citations: 18     Fields:    Translation:Humans
  180. Wiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald E. Baseline Cystatin C Measurement is a Potent Predictor of Adverse Cardiovascular Outcomes Following ACS: A PROVE IT - TIMI 22 Analysis. Circulation. 2006; 114(18 Supplement II):418.
  181. Ruff CT, Wiviott SD, Antman EM, Shui A, McCabe CH, Morrow DA. Effect of Risk on the Benefit of Enoxaparin versus Unfractionated Heparin in Patients with ST-Elevation Myocardial Infarction in the ExTRACT - TIMI 25 Trial. Circulation. 2006; 114(18 Supplement II):814.
  182. Wiviott SD, Stone PH, Bouchard A, Alshaher, Goulder MA, Deitcher SR, Giuglaino RP on Behalf of the ANTHEM - TIMI 32 Investigators. F1.2 Correlates with Ischemia by Holter Monitoring and Is Suppressed by rNAPc2: an ANTHEM - TIMI 32 Biomarker Analysis. Circulation. 2006; 114(18 Supplement II):462.
  183. de Lemos JA, Morrow DA, Wiviott SD, Jarolim P, Blazing MA, Shui A, Sabatine MS, Callif RM, Braunwald E. Evaluation of Monocyte Chemoattractant Protein 1 as a Prognostic Marker in the A to Z Trial. Circulation. 2006; 114(18 Supplement II):648.
  184. Bonaca MP, Wiviott SD, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of peri-procedural MI after percutaneous intervention: A TIMI 26 substudy. Circulation. 2006; 112(17 (Supplement II)):694.
  185. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 Oct; 152(4):627-35. PMID: 16996826.
    Citations: 30     Fields:    Translation:Humans
  186. Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol. 2006 Nov 20; 98(10A):18N-24N. PMID: 17097413.
    Citations: 7     Fields:    Translation:Humans
  187. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6. PMID: 16887854.
    Citations: 9     Fields:    Translation:Humans
  188. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug; 3(8):424-36. PMID: 16874355.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  189. de Lemos JA, Wiviott SD, Murphy SA, Blazing MA, Lewis EF, Califf RM, Pfeffer MA, Braunwald E. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. Am J Cardiol. 2006 Sep 15; 98(6):739-42. PMID: 16950174.
    Citations: 1     Fields:    Translation:Humans
  190. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006 Jul 25; 114(4):281-8. PMID: 16847150.
    Citations: 53     Fields:    Translation:Humans
  191. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42. PMID: 16814646.
    Citations: 9     Fields:    Translation:Humans
  192. Wiviott SD, Morrow DA, Frederick PD, Antman EM, Braunwald E. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1553-8. PMID: 16630990.
    Citations: 6     Fields:    Translation:Humans
  193. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14. PMID: 16534008.
    Citations: 14     Fields:    Translation:Humans
  194. O'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudy. JACC. 2006; 47(4 (Supplement A)):222.
  195. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Bradner JE, Jang IK, Gibson CM, Antman EM. Thrombocytopenia is Associated with Adverse Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting with Acute Coronary Syndromes: A TIMI 11B Substudy. JACC. 2006; 47(4 (Supplement A)):223.
  196. Wiviott SD, Morrow DA, O'Donoghue M, Sabatine MS, Cannon CP, . The TIMI Risk Index for Myocardial Infarction Predicts Post-MI LV Ejection Fraction: A Clarity - TIMI 28 Substudy. JACC. 2006; 47(4 (Supplement A)):224.
  197. Wiviott SD, Tantry US, Gurbel PA. Clinical applications of antiplatelet therapy. Rev Cardiovasc Med. 2006; 7(3):130-46; quiz 148-9. PMID: 17088858.
    Citations:    Fields:    Translation:Humans
  198. Wiviott SD, Michelson AD, Berger PB, Lepor NE, Kereiakes DJ. Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med. 2006; 7(4):214-25. PMID: 17224865.
    Citations: 1     Fields:    Translation:Humans
  199. Wiviott SD, Morrow DA, Sabatine MS, Murphy SA, Winters KJ, Antman EM, Braunwald E. Prasugrel Suppresses the Early Rise of sCD40 Ligand Levels Following PCI Compared to Clopidogrel: A JUMBO - TIMI 26 Substudy. Circulation. 2005; 112(17 (Supplement II) ):432.
  200. Morrow DA, de Lemos JA, Wiviott SD, Blazing MA, Sabatine MS, Rifai N, Califf R, Braunwald E. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients with ACS treated with Statin Therapy: An A to Z Substudy. Circulation. 2005; 112(17 (Supplement II)):387.